Abstract:
Entamoeba histolytica is the etiological agent of amoebic dysentery and amoebic feber abscess. Amoebiasis caused by Entamoeba histolytica associated with high morbidity and mortality continues to be a major public health problem throughout the world. Asymptomatic
individuals account for almost 90% of the infections. Diarrheal disease is the major cause of morbidity and mortality in children in developing countries. Poverty, ignorance, overcrowding,
poor sanitation and malnutrition favor transmission and increased disease burden. To identify, describe the symptoms of E.histolytica and analysis of the interacting: facts and cure of E.histolytica or more precisely in vitro sensitivity study of different brands of Nitazoxanide against clinical isolates of E.histolytica. The parasite count was adjusted to 6.3 x 105 mL_l in a medium. In vitro
drug sensitivity assay of the Nitazoxanide was carried out by using microtiter plates after treatment with different concentration of Nitazoxanide. The experimental concentrations were
0.07, 0.14, 0.28, 0.58, 1.15, 2.3 and 4.6 11M. The viable parasites were counted by beamocytometer. After 24 h incubation the percentages of non viable count of Entamoeba histolytica was
83 .34% and the viable count was 18.65% when the concentration of Nitazoxanide was 0.07 11M.
After 24 h incubation the percentages of non viable count was 94.84% and the viable count was
5.15%when the concentration ofNitazoxanide was 4.6 11M and the initial count was 6.3 x 105 mL The result shows that, Nitazoxanide is effective in the treatment ofa broad range of
parasitic infections. So, the In vitro sensitivity of Nitazoxanide against Entamoeba histolytica is
rugh and it is an innovative treatment option against amoebiasis
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.
